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Abstract 
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by recur-
ring abscesses, nodules, and fistulas predominantly in the groin and axillae. The association 
between HS and Crohn’s disease (CD) has been well documented. Tumor necrosis factor 
(TNF) inhibitors have shown to be effective in treating both HS and CD. We report 2 patients 
who developed HS while on TNF inhibitor treatment for CD. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Crohn’s disease (CD) is an idiopathic chronic inflammatory bowel disease that can affect 
any part of the gastrointestinal tract. Hidradenitis suppurativa (HS) is a chronic inflammato-
ry skin disease characterized by recurrent deep, painful nodules, often of the axilla, groin 
and gluteal areas, that can lead to abscesses and chronic draining sinus tracts [1]. The asso-
ciation between HS and CD is well documented [2]. Patients with inflammatory bowel dis-
ease were approximately nine times more likely to develop HS than the general population 
in a population-based cohort study [3]. Tumor necrosis factor (TNF) inhibitors have been 
shown to be effective in treating recalcitrant HS [4] and moderate to severe CD. [5] Paradox-
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ical psoriatic skin lesions while on anti-TNF therapy have also been well described [6]. We 
present 2 patients who developed HS while receiving treatment with adalimumab for CD. 
We describe some of the immunologic similarities between HS and the psoriasiform rash 
that has been noted on anti-TNF therapy, and explain why HS should be considered as one of 
the rare skin rashes that can develop while a patient is on anti-TNF therapy.  
Case 1 
A 57-year-old African American female presented to our emergency department with a 
6-month history of diarrhea, urgency and tenesmus. She was found to have a perirectal ab-
scess. CT of the abdomen was significant for thickening of the rectum and sigmoid colon. On 
rectal examination, she was noted to have an anal fistula. The perirectal abscess was 
drained, and a seton was placed for the anal fistula. A colonoscopy was performed showing 
erythema and friability consistent with colitis extending to the transverse colon, although 
most pronounced in the sigmoid colon and rectum. The remainder of the colon and the ter-
minal ileum were normal. Biopsies from the involved portion of the colon including the rec-
tum showed acute cryptitis with crypt abscess formation and crypt distortion and were con-
sistent with CD. The patient was started on adalimumab and mesalamine suppositories with 
significant clinical improvement. A follow-up sigmoidoscopy after 8 months showed resolu-
tion of the colitis with only mild proctitis remaining. The patient continues to smoke despite 
counseling.  
Twelve months into treatment, she developed recurrent boils and nodules in her groin. 
Her white blood cell count was normal (6,900/μl). She was started on amoxicillin 875 mg 
and clavulanic acid 125 mg orally twice a day for 10 days. With the suspicion of HS, she was 
referred to the dermatology clinic, and the diagnosis was confirmed. Her skin lesions im-
proved only transiently on the antibiotics. Her disease progressed with multiple boils and 
draining sinus tracts in her groin bilaterally with involvement of her right posterior thigh 
(fig. 1, HS of the right posterior thigh; fig. 2, HS of the left groin) but no axillary involvement. 
She had no prior history of HS or psoriasis. She was started on doxycycline 100 mg orally 
twice a day for 10 days and subsequently also with 10-day courses of cephalexin followed by 
clindamycin with minimal improvement. She was started on suppressive therapy with 
doxycycline 100 mg orally twice a day for 2 months with some improvement. She was transi-
tioned off the antibiotics but the disease recurred. She was treated with several additional 
10-day courses of amoxicillin/clavulanic acid followed by clindamycin. She was placed back 
on suppressive therapy with doxycycline 100 mg orally twice a day for the next 3 months 
followed by minocycline for one month. Over the past 2 years, she received intralesional 
triamcinolone injections on five occasions with little improvement. Currently, she is being 
evaluated by plastic surgery for surgical excision.  
Thirty months into treatment, the patient developed erythematous scaly plaques on her 
back (fig. 3) and at the site of adalimumab injections (fig. 4) and was diagnosed with psoria-
sis. Meanwhile, her CD was well controlled on adalimumab with mild disease confined to the 
rectum with no new fistula formation. It was believed that the adalimumab was causing the 
HS, and the drug was discontinued despite good control of her CD. The patient was switched 
to azathioprine. 
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A 24 year-old African American male non-smoker presented to the emergency room 
with a 1-year history of intermittent bright red blood per rectum with no associated ab-
dominal pain or tenesmus. A colonoscopy was performed showing erythema and friability 
from the rectum to the descending colon. The biopsies showed chronic colitis with granulo-
mas consistent with Crohn’s colitis. He was started on oral Lialda 2.4 g daily, but the disease 
progressed with worsening abdominal pain, diarrhea and the development of an anal fistula. 
Therapy was changed to adalimumab for moderate-severe CD. Nine months into ada-
limumab therapy, he developed a right groin abscess with spontaneous drainage. Initially, it 
was thought that this was folliculitis, and he was treated with Bactrim for 2 weeks. He went 
on to develop multiple nodules in his groin bilaterally with the development of draining si-
nuses but no axillary lesions. He was diagnosed with HS; he had no personal or family histo-
ry of HS. He was treated by dermatology with several 10- to 14-day courses of Bactrim and 
amoxicillin 875 mg/clavulanic acid 125 mg separately with transient improvement. He also 
had surgical excision of these areas and was started on chronic suppressive therapy with 
doxycycline 100 mg orally twice a day. On follow-up, his CD was not well controlled with 
worsening anal fistula, and azathioprine was added to adalimumab. HS also progressed to 
involve his axillary region.  
Discussion 
The association of CD with HS has been determined [2], and TNF antagonists to include 
infliximab have been shown to be helpful in treating patients with CD and HS [2, 7]. TNF 
plays an important role in both CD and HS [7]. CD is characterized by the predominance of 
increased T helper 1 (Th1) lymphocytes with Th17 cytokine expression [8]. TNF antagonists 
such as infliximab and adalimumab have been used to treat diseases such as CD, ulcerative 
colitis and psoriasis.  
Recent studies have implicated anti-TNF antibodies as a cause of psoriasiform skin le-
sions in a small subset of patients with inflammatory bowel disease treated with these 
agents. Historically, this risk has been believed to be very small. However, several studies 
have indicated a higher risk than previously thought. In a recent study of 434 anti-TNF treat-
ed patients with inflammatory bowel disease, 4.8% developed psoriasiform skin lesions [9]. 
Smoking has been shown to be a risk factor for anti-TNF-induced skin lesions [9]. In the 
study by Tillack et al., 76% of the patients that developed psoriasiform skin lesions on anti-
TNF were smokers or ex-smokers [9]. The skin lesions developed on average 13 months 
after initiation of the drug in multiple studies [6, 10], and most of the cases were confined to 
the palmoplantar and scalp areas [10]. In many cases, the drug had to be withdrawn due to 
the rash (43% in the study by Cullen et al. [11]). The psoriasiform rash is believed to be like-
ly a class effect. Of the patients switched to an alternative anti-TNF in the review by Cullen et 
al. [11], 52% were unable to continue the drug due to recurrence of the rash, and only 15% 
were successful in controlling the rash by switching to an alternative anti-TNF. 
In normal skin, TNF-α acts to inhibit the overproduction of interferon-γ [10]. It has been 
theorized that anti-TNF drugs allow unopposed interferon -γ production leading to activa-
tion of T helper cells producing IL-17 [10]. Increased concentrations of IL-17A and IL-23 
have been shown in CD patients who developed skin lesions while on anti-TNF-α therapy 
[12]. It has also been shown that anti-TNF-induced psoriasiform skin lesions have infiltrates 
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of Th17 and Th1 cells, which are similar to the cytokine profile of psoriasis [9], and as noted 
below are similar to the profiles seen in HS. It is believed that the TNF blockade may cause 
the disruption of the cytokine balance in patients with psoriasiform skin lesions leading to 
unopposed interferon-α production by plasmacytoid dendritic cells in these genetically pre-
disposed patients [13]. 
Studies have highlighted skin lesions such as psoriasiform lesions and eczema that can 
develop on ant-TNF therapy, but there is no mention of HS [6, 10, 12]. There was a recent 
case series of several patients that developed HS during treatment with adalimumab [14]. 
This is interesting, as adalimumab has been shown to be effective in treating HS in some 
small studies [4], though not all [15]. There was a range of several weeks to 24 months to the 
onset or exacerbation of HS after starting adalimumab in this series [14]. Two of the 4 pa-
tients in this series did have CD. The development of HS has also been described on etaner-
cept [16]. Also, in a study looking at adalimumab for treatment of HS, 40% of the patients 
withdrew due to worsening of HS [15]. Due to very few reported cases of HS developing 
while on anti-TNF therapy, a conclusion as to whether this is a class effect of TNF antagonists 
cannot be determined. However, the occurrence of anti-TNF-induced psoriasiform lesions is 
believed to be a class effect [9], and this opens up the possibility that anti-TNF-induced HS 
might also be a class effect.  
In the case series by Delobeau et al., 3 of the 4 patients were able to continue on the anti-
TNF, while 1 patient required a switch to ustekinumab [14]. One of the 2 patients in our se-
ries had to be switched to another agent due to poorly controlled HS despite multiple thera-
peutic agents. This is only the second case in which we are aware of the development of HS 
associated with psoriasis [14]. Our series and the series by Delobeau et al. are unique in that 
the patients developed HS while already on adalimumab rather than being started as a po-
tential treatment for HS. 
Increased concentrations of TNF-α has been seen in the serum of patients with HS [17] 
and in HS skin [18]. Adalimumab treatment has been shown to cause a large reduction in the 
number of CD11c+ dendritic cells which are involved in HS pathophysiology [18]. Abundant 
expression of IL-12 and IL-23 was seen in the lesional skin of patients with HS [19]. IL-23 
has an important role in Th17 development, and Th17 cells were seen to infiltrate the le-
sional skin in a study of HS patients [19]. 
The cytokine profiles of HS, psoriasis and anti-TNF induced psoriasiform lesions as not-
ed above are very similar. This opens the possibility that like psoriasis, HS is a rare skin le-
sion that can develop while on anti-TNF therapy and is perhaps due to a cytokine dysregula-
tion as has been seen with TNF antagonists and psoriasiform skin lesions. Ustekinumab is an 
anti-IL-12/IL-23 antibody, which has been used for anti-TNF-induced psoriasiform skin 
lesions [9] and has shown some benefit in CD [20]. This opens the way for a possible use of 
Ustekinumab to treat both CD and HS.  
In conclusion, HS should be considered as a potential rare paradoxical side effect of anti-
TNF therapy. 
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Fig. 4. Psoriasiform skin lesion at the adalimumab injection site. 
 
